Which has stronger valuation and earnings, SANA or AVXL?

Anavex Life Sciences is trading at a lower price-to-earnings ratio than Sana Biotechnology, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sana Biotechnology N/A N/A -$244.17M -$0.93 N/A Anavex Life Sciences N/A N/A -$46.38M -$0.39 N/A

Is SANA or AVXL more profitable?

Anavex Life Sciences' return on equity of -32.73% beat Sana Biotechnology's return on equity. Company Net Margins Return on Equity Return on Assets Sana Biotechnology N/A -108.01% -40.68% Anavex Life Sciences N/A -32.73% -30.15%

Does the media favor SANA or AVXL?

In the previous week, Anavex Life Sciences had 3 more articles in the media than Sana Biotechnology. MarketBeat recorded 7 mentions for Anavex Life Sciences and 4 mentions for Sana Biotechnology. Anavex Life Sciences' average media sentiment score of 0.93 beat Sana Biotechnology's score of 0.26 indicating that Anavex Life Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sana Biotechnology 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Anavex Life Sciences 0 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to AVXL or TBPH?

In the previous week, Anavex Life Sciences had 4 more articles in the media than Theravance Biopharma. MarketBeat recorded 7 mentions for Anavex Life Sciences and 3 mentions for Theravance Biopharma. Theravance Biopharma's average media sentiment score of 1.61 beat Anavex Life Sciences' score of 0.93 indicating that Theravance Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Anavex Life Sciences 0 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Theravance Biopharma 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media refer more to AVXL or ABUS?

In the previous week, Anavex Life Sciences had 4 more articles in the media than Arbutus Biopharma. MarketBeat recorded 7 mentions for Anavex Life Sciences and 3 mentions for Arbutus Biopharma. Arbutus Biopharma's average media sentiment score of 1.19 beat Anavex Life Sciences' score of 0.93 indicating that Arbutus Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Anavex Life Sciences 0 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arbutus Biopharma 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, AVXL or ANNX?

Anavex Life Sciences is trading at a lower price-to-earnings ratio than Annexon, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Anavex Life Sciences N/A N/A -$46.38M -$0.39 N/A Annexon N/A N/A -$206.69M -$1.22 N/A

Is AVXL or ANNX more profitable?

Anavex Life Sciences' return on equity of -32.73% beat Annexon's return on equity. Company Net Margins Return on Equity Return on Assets Anavex Life Sciences N/A -32.73% -30.15% Annexon N/A -101.19% -75.99%

Does the media refer more to AVXL or ANNX?

In the previous week, Anavex Life Sciences had 2 more articles in the media than Annexon. MarketBeat recorded 7 mentions for Anavex Life Sciences and 5 mentions for Annexon. Annexon's average media sentiment score of 1.21 beat Anavex Life Sciences' score of 0.93 indicating that Annexon is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Anavex Life Sciences 0 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Annexon 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer AMPH or AVXL?

In the previous week, Anavex Life Sciences had 2 more articles in the media than Amphastar Pharmaceuticals. MarketBeat recorded 7 mentions for Anavex Life Sciences and 5 mentions for Amphastar Pharmaceuticals. Anavex Life Sciences' average media sentiment score of 0.93 beat Amphastar Pharmaceuticals' score of 0.26 indicating that Anavex Life Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amphastar Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Anavex Life Sciences 0 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Anavex Life Sciences (AVXL) Competitors

$2.90 +0.16 (+5.64%)

As of 12:51 PM Eastern

Compare

AVXL vs. SANA, TBPH, ABUS, ANNX, and AMPH

Should you buy Anavex Life Sciences stock or one of its competitors? MarketBeat compares Anavex Life Sciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Anavex Life Sciences include Sana Biotechnology (SANA), Theravance Biopharma (TBPH), Arbutus Biopharma (ABUS), Annexon (ANNX), and Amphastar Pharmaceuticals (AMPH).

How does Anavex Life Sciences compare to Sana Biotechnology?

Sana Biotechnology (NASDAQ:SANA) and Anavex Life Sciences (NASDAQ:AVXL) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, profitability, media sentiment, valuation, risk, dividends and analyst recommendations.

In the previous week, Anavex Life Sciences had 3 more articles in the media than Sana Biotechnology. MarketBeat recorded 7 mentions for Anavex Life Sciences and 4 mentions for Sana Biotechnology. Anavex Life Sciences' average media sentiment score of 0.93 beat Sana Biotechnology's score of 0.26 indicating that Anavex Life Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sana Biotechnology	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Anavex Life Sciences	0 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Sana Biotechnology has a beta of 2.13, suggesting that its share price is 113% more volatile than the broader market. Comparatively, Anavex Life Sciences has a beta of 1.15, suggesting that its share price is 15% more volatile than the broader market.

Sana Biotechnology currently has a consensus price target of $9.50, suggesting a potential upside of 203.03%. Anavex Life Sciences has a consensus price target of $21.33, suggesting a potential upside of 634.37%. Given Anavex Life Sciences' higher possible upside, analysts plainly believe Anavex Life Sciences is more favorable than Sana Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sana Biotechnology	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Anavex Life Sciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Anavex Life Sciences' return on equity of -32.73% beat Sana Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sana Biotechnology	N/A	-108.01%	-40.68%
Anavex Life Sciences	N/A	-32.73%	-30.15%

Anavex Life Sciences is trading at a lower price-to-earnings ratio than Sana Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sana Biotechnology	N/A	N/A	-$244.17M	-$0.93	N/A
Anavex Life Sciences	N/A	N/A	-$46.38M	-$0.39	N/A

88.2% of Sana Biotechnology shares are owned by institutional investors. Comparatively, 31.6% of Anavex Life Sciences shares are owned by institutional investors. 25.4% of Sana Biotechnology shares are owned by company insiders. Comparatively, 11.0% of Anavex Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Anavex Life Sciences beats Sana Biotechnology on 7 of the 13 factors compared between the two stocks.

How does Anavex Life Sciences compare to Theravance Biopharma?

Anavex Life Sciences (NASDAQ:AVXL) and Theravance Biopharma (NASDAQ:TBPH) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, profitability, risk, institutional ownership, media sentiment, analyst recommendations and dividends.

Theravance Biopharma has higher revenue and earnings than Anavex Life Sciences. Anavex Life Sciences is trading at a lower price-to-earnings ratio than Theravance Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anavex Life Sciences	N/A	N/A	-$46.38M	-$0.39	N/A
Theravance Biopharma	$107.46M	8.09	$105.89M	$2.20	7.67

In the previous week, Anavex Life Sciences had 4 more articles in the media than Theravance Biopharma. MarketBeat recorded 7 mentions for Anavex Life Sciences and 3 mentions for Theravance Biopharma. Theravance Biopharma's average media sentiment score of 1.61 beat Anavex Life Sciences' score of 0.93 indicating that Theravance Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Anavex Life Sciences	0 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Theravance Biopharma	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Anavex Life Sciences has a beta of 1.15, suggesting that its stock price is 15% more volatile than the broader market. Comparatively, Theravance Biopharma has a beta of 0.19, suggesting that its stock price is 81% less volatile than the broader market.

Anavex Life Sciences currently has a consensus price target of $21.33, suggesting a potential upside of 634.37%. Theravance Biopharma has a consensus price target of $19.40, suggesting a potential upside of 15.03%. Given Anavex Life Sciences' stronger consensus rating and higher probable upside, analysts clearly believe Anavex Life Sciences is more favorable than Theravance Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anavex Life Sciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Theravance Biopharma	0 Sell rating(s)	8 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

31.6% of Anavex Life Sciences shares are owned by institutional investors. Comparatively, 99.1% of Theravance Biopharma shares are owned by institutional investors. 11.0% of Anavex Life Sciences shares are owned by company insiders. Comparatively, 7.7% of Theravance Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Theravance Biopharma has a net margin of 104.34% compared to Anavex Life Sciences' net margin of 0.00%. Theravance Biopharma's return on equity of 18.84% beat Anavex Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anavex Life Sciences	N/A	-32.73%	-30.15%
Theravance Biopharma	104.34%	18.84%	10.94%

Summary

Theravance Biopharma beats Anavex Life Sciences on 9 of the 15 factors compared between the two stocks.

How does Anavex Life Sciences compare to Arbutus Biopharma?

Anavex Life Sciences (NASDAQ:AVXL) and Arbutus Biopharma (NASDAQ:ABUS) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, earnings, risk, valuation, profitability, institutional ownership, dividends and analyst recommendations.

Arbutus Biopharma has a net margin of 83.95% compared to Anavex Life Sciences' net margin of 0.00%. Arbutus Biopharma's return on equity of 129.32% beat Anavex Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anavex Life Sciences	N/A	-32.73%	-30.15%
Arbutus Biopharma	83.95%	129.32%	112.24%

Anavex Life Sciences has a beta of 1.15, suggesting that its share price is 15% more volatile than the broader market. Comparatively, Arbutus Biopharma has a beta of 0.62, suggesting that its share price is 38% less volatile than the broader market.

In the previous week, Anavex Life Sciences had 4 more articles in the media than Arbutus Biopharma. MarketBeat recorded 7 mentions for Anavex Life Sciences and 3 mentions for Arbutus Biopharma. Arbutus Biopharma's average media sentiment score of 1.19 beat Anavex Life Sciences' score of 0.93 indicating that Arbutus Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Anavex Life Sciences	0 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Arbutus Biopharma	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Anavex Life Sciences presently has a consensus target price of $21.33, suggesting a potential upside of 634.37%. Arbutus Biopharma has a consensus target price of $5.00, suggesting a potential upside of 13.77%. Given Anavex Life Sciences' stronger consensus rating and higher possible upside, equities analysts plainly believe Anavex Life Sciences is more favorable than Arbutus Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anavex Life Sciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Arbutus Biopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Arbutus Biopharma has higher revenue and earnings than Anavex Life Sciences. Anavex Life Sciences is trading at a lower price-to-earnings ratio than Arbutus Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anavex Life Sciences	N/A	N/A	-$46.38M	-$0.39	N/A
Arbutus Biopharma	$191.45M	4.53	-$33.50M	$0.83	5.30

31.6% of Anavex Life Sciences shares are owned by institutional investors. Comparatively, 43.8% of Arbutus Biopharma shares are owned by institutional investors. 11.0% of Anavex Life Sciences shares are owned by insiders. Comparatively, 19.9% of Arbutus Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Arbutus Biopharma beats Anavex Life Sciences on 10 of the 15 factors compared between the two stocks.

How does Anavex Life Sciences compare to Annexon?

Anavex Life Sciences (NASDAQ:AVXL) and Annexon (NASDAQ:ANNX) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, earnings, profitability, institutional ownership, valuation, media sentiment and analyst recommendations.

Anavex Life Sciences is trading at a lower price-to-earnings ratio than Annexon, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anavex Life Sciences	N/A	N/A	-$46.38M	-$0.39	N/A
Annexon	N/A	N/A	-$206.69M	-$1.22	N/A

Anavex Life Sciences has a beta of 1.15, suggesting that its stock price is 15% more volatile than the broader market. Comparatively, Annexon has a beta of 1.16, suggesting that its stock price is 16% more volatile than the broader market.

Anavex Life Sciences currently has a consensus price target of $21.33, suggesting a potential upside of 634.37%. Annexon has a consensus price target of $15.33, suggesting a potential upside of 197.22%. Given Anavex Life Sciences' stronger consensus rating and higher probable upside, equities research analysts clearly believe Anavex Life Sciences is more favorable than Annexon.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anavex Life Sciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Annexon	3 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.20

31.6% of Anavex Life Sciences shares are owned by institutional investors. 11.0% of Anavex Life Sciences shares are owned by insiders. Comparatively, 10.3% of Annexon shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Anavex Life Sciences' return on equity of -32.73% beat Annexon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anavex Life Sciences	N/A	-32.73%	-30.15%
Annexon	N/A	-101.19%	-75.99%

In the previous week, Anavex Life Sciences had 2 more articles in the media than Annexon. MarketBeat recorded 7 mentions for Anavex Life Sciences and 5 mentions for Annexon. Annexon's average media sentiment score of 1.21 beat Anavex Life Sciences' score of 0.93 indicating that Annexon is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Anavex Life Sciences	0 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Annexon	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Anavex Life Sciences beats Annexon on 9 of the 13 factors compared between the two stocks.

How does Anavex Life Sciences compare to Amphastar Pharmaceuticals?

Amphastar Pharmaceuticals (NASDAQ:AMPH) and Anavex Life Sciences (NASDAQ:AVXL) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, dividends, institutional ownership, risk, media sentiment, earnings, profitability and analyst recommendations.

Amphastar Pharmaceuticals has higher revenue and earnings than Anavex Life Sciences. Anavex Life Sciences is trading at a lower price-to-earnings ratio than Amphastar Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amphastar Pharmaceuticals	$719.89M	1.22	$98.09M	$1.66	12.05
Anavex Life Sciences	N/A	N/A	-$46.38M	-$0.39	N/A

Amphastar Pharmaceuticals currently has a consensus target price of $22.00, suggesting a potential upside of 10.03%. Anavex Life Sciences has a consensus target price of $21.33, suggesting a potential upside of 634.37%. Given Anavex Life Sciences' stronger consensus rating and higher probable upside, analysts plainly believe Anavex Life Sciences is more favorable than Amphastar Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amphastar Pharmaceuticals	2 Sell rating(s)	6 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75
Anavex Life Sciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

65.1% of Amphastar Pharmaceuticals shares are held by institutional investors. Comparatively, 31.6% of Anavex Life Sciences shares are held by institutional investors. 29.6% of Amphastar Pharmaceuticals shares are held by company insiders. Comparatively, 11.0% of Anavex Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Amphastar Pharmaceuticals has a net margin of 11.00% compared to Anavex Life Sciences' net margin of 0.00%. Amphastar Pharmaceuticals' return on equity of 15.12% beat Anavex Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amphastar Pharmaceuticals	11.00%	15.12%	7.14%
Anavex Life Sciences	N/A	-32.73%	-30.15%

Amphastar Pharmaceuticals has a beta of 0.89, suggesting that its share price is 11% less volatile than the broader market. Comparatively, Anavex Life Sciences has a beta of 1.15, suggesting that its share price is 15% more volatile than the broader market.

In the previous week, Anavex Life Sciences had 2 more articles in the media than Amphastar Pharmaceuticals. MarketBeat recorded 7 mentions for Anavex Life Sciences and 5 mentions for Amphastar Pharmaceuticals. Anavex Life Sciences' average media sentiment score of 0.93 beat Amphastar Pharmaceuticals' score of 0.26 indicating that Anavex Life Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amphastar Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Anavex Life Sciences	0 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Amphastar Pharmaceuticals beats Anavex Life Sciences on 9 of the 15 factors compared between the two stocks.

Get Anavex Life Sciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AVXL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AVXL vs. The Competition

Export

Metric	Anavex Life Sciences	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$269.21M	$3.52B	$6.80B	$12.66B
Dividend Yield	N/A	3.78%	2.59%	10.03%
P/E Ratio	-7.45	7.38	282.16	25.05
Price / Sales	N/A	1,220.59	576.18	79.91
Price / Cash	N/A	44.80	28.60	46.71
Price / Book	2.64	16.79	10.96	6.18
Net Income	-$46.38M	-$12.56M	$3.49B	$347.61M
7 Day Performance	16.20%	-0.84%	0.45%	0.71%
1 Month Performance	5.25%	-7.59%	-4.26%	-3.75%
1 Year Performance	-74.06%	49.20%	63.09%	20.17%

Anavex Life Sciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AVXL Anavex Life Sciences	1.9004 of 5 stars	$2.91 +5.6%	$21.33 +634.4%	-75.4%	$269.21M	N/A	N/A	40	News Coverage Earnings Report
SANA Sana Biotechnology	2.2768 of 5 stars	$3.28 +3.1%	$9.50 +189.6%	-19.9%	$884.97M	N/A	N/A	380	Upcoming Earnings
TBPH Theravance Biopharma	2.7485 of 5 stars	$16.86 flat	$19.40 +15.1%	+54.7%	$869.18M	$107.46M	7.66	110	News Coverage Positive News
ABUS Arbutus Biopharma	1.9856 of 5 stars	$4.41 +0.7%	$5.00 +13.4%	+32.7%	$865.22M	$14.08M	5.31	90	Positive News Upcoming Earnings Gap Up
ANNX Annexon	3.9901 of 5 stars	$5.13 -1.7%	$15.33 +198.9%	+107.8%	$855.26M	N/A	N/A	60	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AVXL) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Anavex Life Sciences (AVXL) Competitors

AVXL vs. SANA, TBPH, ABUS, ANNX, and AMPH

How does Anavex Life Sciences compare to Sana Biotechnology?

Summary

How does Anavex Life Sciences compare to Theravance Biopharma?

Summary

How does Anavex Life Sciences compare to Arbutus Biopharma?

Summary

How does Anavex Life Sciences compare to Annexon?

Summary

How does Anavex Life Sciences compare to Amphastar Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVXL vs. The Competition

Anavex Life Sciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Anavex Life Sciences (AVXL) Competitors

AVXL vs. SANA, TBPH, ABUS, ANNX, and AMPH

How does Anavex Life Sciences compare to Sana Biotechnology?

Does the media favor SANA or AVXL?

Which has more volatility and risk, SANA or AVXL?

Do analysts recommend SANA or AVXL?

Is SANA or AVXL more profitable?

Which has stronger valuation and earnings, SANA or AVXL?

Do institutionals and insiders hold more shares of SANA or AVXL?

Summary

How does Anavex Life Sciences compare to Theravance Biopharma?

Which has higher valuation & earnings, AVXL or TBPH?

Does the media refer more to AVXL or TBPH?

Which has more volatility & risk, AVXL or TBPH?

Do analysts recommend AVXL or TBPH?

Do insiders & institutionals hold more shares of AVXL or TBPH?

Is AVXL or TBPH more profitable?

Summary

How does Anavex Life Sciences compare to Arbutus Biopharma?

Is AVXL or ABUS more profitable?

Which has more volatility and risk, AVXL or ABUS?

Does the media refer more to AVXL or ABUS?

Do analysts recommend AVXL or ABUS?

Which has preferable valuation and earnings, AVXL or ABUS?

Do institutionals and insiders hold more shares of AVXL or ABUS?

Summary

How does Anavex Life Sciences compare to Annexon?

Which has stronger earnings & valuation, AVXL or ANNX?

Which has more risk & volatility, AVXL or ANNX?

Do analysts recommend AVXL or ANNX?

Do institutionals & insiders hold more shares of AVXL or ANNX?

Is AVXL or ANNX more profitable?

Does the media refer more to AVXL or ANNX?

Summary

How does Anavex Life Sciences compare to Amphastar Pharmaceuticals?

Which has higher valuation and earnings, AMPH or AVXL?

Do analysts rate AMPH or AVXL?

Do insiders & institutionals believe in AMPH or AVXL?

Is AMPH or AVXL more profitable?

Which has more volatility and risk, AMPH or AVXL?

Does the media prefer AMPH or AVXL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVXL vs. The Competition

Anavex Life Sciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools